Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.52	$1.14	$0.40 ▼ $2.71	$213.65M	1.11	2.15 million shs	3.90 million shs
IPHA Innate Pharma	$2.16 -1.8%	$2.04	$1.29 ▼ $3.51	$199.10M	0.27	186,368 shs	8,120 shs
KOD Kodiak Sciences	$3.45 -3.4%	$3.32	$1.92 ▼ $11.60	$182.04M	2.42	344,373 shs	590,286 shs
RNTX Rein Therapeutics	$1.92 -1.0%	$1.80	$1.35 ▼ $4.40	$42.54M	1.78	53,308 shs	14,382 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	+13.00%	+214.21%	+287.51%	+48.24%
IPHA Innate Pharma	0.00%	+0.23%	-4.42%	+3.35%	-21.17%
KOD Kodiak Sciences	0.00%	+0.29%	-28.13%	-11.54%	+8.49%
RNTX Rein Therapeutics	0.00%	-6.34%	+5.49%	+1.05%	+191,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.4711 of 5 stars	3.5	2.0	0.0	4.7	3.4	2.5	1.3
IPHA Innate Pharma	3.2142 of 5 stars	3.8	5.0	0.0	0.0	3.4	1.7	0.0
KOD Kodiak Sciences	4.1477 of 5 stars	3.0	3.0	0.0	4.6	2.0	3.3	0.6
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	111.64% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	409.26% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	160.87% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNTX, KOD, IPHA, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/28/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.50
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$147.56M	1.38	N/A	N/A	($0.71) per share	-3.55
IPHA Innate Pharma	$12.62M	15.78	N/A	N/A	$0.69 per share	3.13
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$570K	$0.48	14.82	N/A	N/A	10.96%	-41.47%	8.11%	8/7/2025 (Estimated)
IPHA Innate Pharma	-$8.19M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	8/13/2025 (Estimated)
RNTX Rein Therapeutics	-$15.73M	-$2.86	N/A	N/A	N/A	N/A	-74.08%	-27.93%	N/A

Latest RNTX, KOD, IPHA, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
4/7/2025	Q4 2024	RNTX Rein Therapeutics	N/A	-$0.26	N/A	-$1.89	N/A	N/A
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.04	1.04
IPHA Innate Pharma	0.92	2.92	N/A
KOD Kodiak Sciences	N/A	8.42	8.42
RNTX Rein Therapeutics	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
IPHA Innate Pharma	0.16%
KOD Kodiak Sciences	89.06%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	7.00%
IPHA Innate Pharma	31.89%
KOD Kodiak Sciences	45.30%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
IPHA Innate Pharma	220	92.18 million	57.10 million	Not Optionable
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
RNTX Rein Therapeutics	9	22.15 million	20.56 million	N/A

RNTX, KOD, IPHA, and CTMX Headlines

Recent News About These Companies

RNTX Rein Therapeutics Inc.

June 1 at 7:08 AM | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 28, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

Rein Therapeutics reports IPF and PASC-F treatment progress

April 18, 2025 | uk.investing.com

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

April 16, 2025 | markets.businessinsider.com

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

April 15, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

April 8, 2025 | finanznachrichten.de

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

April 7, 2025 | prnewswire.com

Rein Therapeutics Inc. (RNTX)

March 25, 2025 | ca.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, KOD, IPHA, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.52 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.64 +0.12 (+4.56%)

As of 08:39 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Innate Pharma NASDAQ:IPHA

$2.16 -0.04 (-1.82%)

Closing price 05/30/2025 03:56 PM Eastern

Extended Trading

$2.19 +0.03 (+1.39%)

As of 07:48 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Kodiak Sciences NASDAQ:KOD

$3.45 -0.12 (-3.36%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.25 (+7.10%)

As of 08:19 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Rein Therapeutics NASDAQ:RNTX

$1.92 -0.02 (-1.03%)

As of 05/30/2025 03:45 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time